ReviewNanomedicine (London, England)2025
The rationality guidance index: a framework for reducing redundancy in nanomedicine innovation.
Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanocarriers have transformed drug delivery by improving bioavailability, enabling targeted action, and reducing systemic toxicity. Despite these advances, the field has become saturated with structurally and functionally similar platforms, leading to redundancy and limited translational progress. This work critically analyzes the scientific and systemic drivers of redundancy, including design convergence, patent-driven modifications, novelty-focused academic incentives, and insufficient comparative standards. To address these challenges, a rational innovation framework is proposed, grounded in needs-based design, comparative benchmarking, predictive modeling, and resource-conscious decision-making. Within this framework, the Rationality Guidance Index (RGI) is introduced as a semi-quantitative pre-initiation triage tool that balances clinical need, innovation value, and translational feasibility. Designed for academic and innovator contexts, the RGI complements existing frameworks such as DELIVER and the 6Rs roadmap by identifying projects at high risk of redundancy before resource-intensive development. The adoption of rational innovation strategies, supported by structured decision-making tools, is essential to enhance clinical success rates and ensure that advances in nanomedicine translate into meaningful patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.